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The inherent risks associated with vector insertion in 
gene therapy need to be carefully assessed. We ana-
lyzed the genome-wide distributions of Sleeping Beauty 
(SB) and piggyBac (PB) transposon insertions as well as 
MLV retrovirus and HIV lentivirus insertions in human 
CD4+ T cells with respect to a panel of 40 chromatin 
states. The distribution of SB transposon insertions dis-
played the least deviation from random, while the PB 
transposon and the MLV retrovirus showed unexpected 
parallels across all chromatin states. Both MLV and PB 
insertions are enriched at transcriptional start sites (TSSs) 
and co-localize with BRD4-associated sites. We demon-
strate physical interaction between the PB transposase 
and bromodomain and extraterminal domain pro-
teins (including BRD4), suggesting convergent evolu-
tion of a tethering mechanism that directs integrating 
genetic elements into TSSs. We detect unequal biases 
across the four systems with respect to targeting genes 
whose deregulation has been previously linked to seri-
ous adverse events in gene therapy clinical trials. The SB 
transposon has the highest theoretical chance of target-
ing a safe harbor locus in the human genome. The data 
underscore the significance of vector choice to reduce 
the mutagenic load on cells in clinical applications.
Received 28 July 2015; accepted 6 January 2016; advance online  
publication 9 February 2016. doi:10.1038/mt.2016.11
INTRODUCTION
The ability to efficiently deliver foreign genes into cells offers 
opportunities to use gene therapy to correct genetic diseases 
and to augment cellular processes to achieve a therapeutic effect 
(reviewed in refs. 1,2). Hematopoietic stem cell (HSC)-based 
gene therapy has clearly provided therapeutic benefit in primary 
immunodeficiencies (including SCID-X1, ADA-SCID), thalas-
semia, and leukodystrophies.3–6 However, uncontrolled integra-
tion of contemporary retroviral gene therapy vectors may result in 
insertional mutagenesis by activating oncogenes,7,8 as observed in 
clinical trials for SCID-X19–12, X-CGD,13 and WAS.14 In contrast to 
HSC-based gene therapy, leukemia was never observed in preclin-
ical animal models or clinical trials involving gene transfer into 
peripheral blood-derived T lymphocytes.15,16 Thus, mature T cells 
seem to be less susceptible to transformation by genotoxic events 
than are HSCs, and retroviral gene therapy in T cells therefore has 
not been thought to involve a major risk of insertional mutagene-
sis and development of cancer. Importantly, however, recent stud-
ies indicate that some HIV integrations into genes associated with 
cancer or cell cycle regulation may confer a survival advantage of 
HIV-infected cells and thus a clonal imbalance of HIV integra-
tions in AIDS patients.17,18
The risk of insertional oncogenesis in gene therapy is inher-
ently linked to a fundamental step of the life cycle of mobile 
genetic elements (retroviruses and transposons): genomic inser-
tion. Vector architecture, the enhancer/promoter elements used 
to drive transgene transcription, copy numbers, the underlying 
disease, and insertion site selection properties of the vectors can 
strongly influence the actual risk of insertional oncogenesis. There 
is a wide spectrum of specificity in target site selection by mobile 
genetic elements. For example, retroviral/lentiviral integration 
displays little specificity on the primary DNA sequence level but 
biased patterns of distribution on the genome level, which is likely 
due to interaction of the viral components with certain host pro-
teins or recognition of different chromatin states of the chromo-
somes during integration.19 For example, the bias of HIV toward 
integration into active cellular transcription units20 was proposed 
to be due to tethering interactions with cellular proteins rather 
than to chromatin accessibility. In particular, the cellular lens 
 epithelium-derived growth factor (LEDGF)/p75 was shown to 
influence HIV target site selection.21
Similar studies showed that MLV has a strong preference for 
integrating into regions surrounding transcriptional start sites 
(TSSs).22 However, a recently generated, high-resolution inser-
tion site map based on >3 million unique integration events in 
two ENCODE-characterized human cell lines revealed that a 
subset of strong enhancers and active promoters characterized by 
high enrichment of multiple marks of active chromatin (includ-
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are preferentially targeted, and thus, these regions are better pre-
dictors of MLV integration than TSSs.23 Finally, it was recently 
reported that the cellular bromodomain and extraterminal (BET) 
domain proteins (BRD2, BRD3, and BRD4) physically interact 
with the MLV IN.24–26 The N-terminal bromodomains of BET 
proteins bind to acetylated H3 and H4 tails,27 which are associ-
ated with TSSs. Thus, MLV integration site distribution parallels 
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disruption of the interaction with BET proteins through truncated 
IN mutants was recently shown to affect the genome-wide integra-
tion profile of MLV vectors.28 Finally, expression of an engineered 
fusion protein composed of the IN-binding domain of BET and 
the chromatin interaction domain of the lentiviral targeting factor 
LEDGF/p75 was shown to retarget MLV integration away from 
TSSs and into the body of actively transcribed genes, resembling 
the HIV integration pattern.25 These data collectively suggest that 
the BET proteins act as bimodal tethers that link MLV IN to TSSs 
in chromatin.
Sleeping Beauty (SB) is the most thoroughly studied vertebrate 
transposon to date, and it has shown highly efficient transposition 
in different somatic tissues of a wide range of vertebrate species 
including humans (reviewed in refs. 29,30). SB has been shown 
to provide long-term transgene expression in preclinical animal 
models (see refs. 31–33 for recent reviews) and is currently under 
clinical evaluation as an integrating, nonviral vector system for 
gene therapy.34,35 The SB transposon preferentially inserts into TA 
dinucleotides and shows additional target site preferences based 
on physical properties of the DNA.36,37 On the genomic scale, SB 
transposons exhibit a close-to-random integration profile with 
a slight bias toward integration into genes and their upstream 
regulatory sequences in cultured mammalian cell lines;38–43 this 
tendency, however, is not as pronounced as seen for viral vectors. 
The piggyBac (PB) element, a DNA transposon isolated from the 
cabbage looper moth, has shown transpositional activity in mouse 
and human cells and thus also has a potential as a vector in gene 
therapy.44 PB preferentially integrates into TTAA sequences,45 with 
a significant bias toward transcriptionally active regions includ-
ing genes, TSSs, and DNaseI hypersensitive sites in mammalian 
cells39,43,44,46–48 and in Drosophila.49 Target site selection properties 
of the SB and PB transposons together with the Mouse Mammary 
Tumor Virus (MMTV) have been comparatively analyzed in great 
detail in mouse embryonic stem (ES) cells;50 however, a similar 
analysis of these transposons in therapeutically relevant human 
cell types and against retroviral vector systems that are cur-
rently used in several gene therapy clinical trials (Journal of Gene 
Medicine Clinical Trial Database, 2015) has been lacking.
Although characterization of the target site selection proper-
ties of different vector systems still falls short of predicting the 
actual risk of insertional oncogenesis in a clinical trial, it is highly 
useful for ranking the different vector types and designs according 
to their genotoxic potential.2 Thus, we have undertaken a com-
parative study addressing target site selection properties of the SB 
and PB transposons as well as the MLV and HIV viral systems 
in primary human CD4+ T cells. We have chosen this cell type 
due to the availability of the rich genome-wide mapping data for 
chromatin marks as well as other genomic features and because 
currently running phase 1 gene therapy clinical trials with SB use 
this cell type as target.35 We find that, in contrast to PB, MLV and 
HIV that all show biased insertion patterns into expressed genes, 
the SB transposon displays a close-to-random insertion profile, 
thereby supporting relative safety of SB in human applications. 
The PB transposon shows an intriguing, MLV-like profile with 
pronounced preference for integrating into the  5′-transcriptional 
regulatory regions of genes, and we show that this is largely 
shaped by physical interaction between the transposase and BET 
proteins. We describe an additional tethering mechanism that 
involves chromatin-associated transposase molecules in SB trans-
position. In sum, our findings have important implications for 
the safety of these integration systems for genome engineering, 
including human gene therapy.
RESULTS
Genomic states define chromosomal regions 
preferred for integration
In order to generate datasets representing de novo transpo-
son integration sites, primary human CD4+ T cells were elec-
troporated with pairs of transposase and transposon plasmids 
of the SB and the PB systems (Supplementary Figure S1a). 
Linear  amplification-mediated PCR was used for the recov-
ery of genomic transposon integrations, and the PCR librar-
ies were sequenced using the Illumina/Solexa HiSeq Platform 
(Supplementary Figure S1b). The retrieved transposon integra-
tion sites (Supplementary Figure S1c) for the SB (8,290 sites) and 
PB (8,954 sites) systems were used together with datasets gen-
erated in CD4+ human T cells with the MLV retrovirus (66,764 
sites)51 and with the HIV lentivirus (7,765 sites)52 in a comparative 
manner for all downstream analyses (schematic maps of all four 
vectors are shown in Supplementary Figure S1d). Consensus 
sequences at transposon integration sites revealed that the highly 
preferred TA target site dinucleotides for SB and the TTAA tetra-
nucleotide motif for PB are embedded in AT-rich DNA, as noted 
previously43,53 (Supplementary Figure S2a). In contrast, the 
viral systems display very weak preferences at the primary DNA 
sequence level for integration (Supplementary Figure S2a,b).
Mapping of SB and PB insertions on the human chromo-
some set revealed an overall wide distribution across the human 
genome (Supplementary Figure S3). In the context of describ-
ing insertional preferences on a genome-wide scale, it has been 
recently shown that chromatin “states” defined by co-occur-
rence of multiple chromatin marks are far better predictors for 
integration than any of those marks separately.23 Keeping this 
in mind, we used an unsupervised machine-learning approach 
(ChromHMM, which applies a Hidden Markov Model)54 in 
order to define 40 different genomic states, each characterized 
Figure 1  Analysis of chromatin states. The ChromHMM software (which uses a Hidden Markov Model (HMM)) was applied to derive 40 different 
genomic states from 70 empirical datasets including histone marks, DNA methylation, chromatin accessibility, or the binding sites of numerous tran-
scription factors, polymerases, histone acetylases, and deacetylases. (a) The output probabilities of the trained HMM. Black: the state is completely 
covered by regions defined in the given dataset; white: the state and the dataset are disjoint. (b) Enrichments of each state for a set of genomic 
regions, computed using the OverlapEnrichment function of ChromHMM. (c) Genome coverage of states. More frequent states correspond to darker 
colors. (d–f) Enrichment of integration sites versus control sites at the different (d) states, (e) dataset regions, or (f) genomic features. Blue: deple-
tion of integration sites at the given regions; red: enrichment of integration sites. If the depletion/enrichment of integration sites at a given region is 
not significant (i.e., Fisher’s exact test P value > 0.05), then the field is marked gray. (g) Comparison of PB and MLV. The scatter plots show the fold 
enrichments of integration sites versus control sites of MLV compared to PB at 40 states, 70 datasets, and 16 genomic features, as described in a–f. 
Gray dots correspond to region sets in which PB or MLV show no significant enrichment/depletion of integrations.
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by a coherent pattern of presence or absence of genomic 
characteristics specified in 70 different datasets (Figure  1a). 
Although it is not obvious how to assign a clear definition to 
each of these automatically generated states, one can get hints 
about possible functions of the different states from Figure 1b, 
which shows the level of enrichment or depletion of states 
within certain genomic features. For example, state 1 represents 
the genomic (intergenic) background without a marked asso-
ciation with any specific measured characteristics. States 2–7 
correspond to heterochromatic regions, where state 6 specifi-
cally covers methylated DNA. States 11–13 are weak enhancer 
regions, mainly inside gene bodies, while states 27, 33, and 34 
are strong enhancers located in intergenic regions. States 34 and 
37–40 are promoter regions, whereas state 39 is associated with 
a strong histone acetylation signal. State 34 marks active pro-
moters, whereas promoters in state 37 feature a less accessible 
chromatin and tend to be associated with low or unexpressed 
genes. States 16, 17, 31, and 32 correspond to transcriptional 
ends of active genes. The tool then assigned to each genomic 
region one of these states. The states cover between 25 % (state 
1) and 0.01% (state 33) of the genome (Figure  1c). We then 
determined the fold enrichments of integration sites versus 
control sites at the different states (Figure 1d), dataset regions 
(Figure  1e), and genomic features (Figure  1f). Unexpectedly, 
the enrichments for PB and MLV are very tightly correlated in 
all three cases (coefficients of determination R2 between 0.90 
and 0.95; Figure  1g). In contrast, SB and PB display much 
weaker correlation (R2 between 0.18 and 0.43, data not shown).
Figure 2 Analysis of integration frequencies relative to annotated genes. (a) Distribution of distance between integration sites outside of genes and 
the nearest gene. The figures were created using the R density function with Gaussian kernel and bandwidth 0.2 on the log10 distances. The dashed lines 
show the median distances for SB (48.1 kb), PB (24.3 kb), HIV (13.2 kb), MLV (12.4 kb), and the random controls (85.6 kb). (b) Fold enrichments (i.e., the 
proportion of experimentally determined integration sites falling into a given set of regions divided by the proportion of control sites falling into the same 
set of regions) of integrations sites within RefSeq genes and of integration sites found upstream (−50 kb to −1 kb) or downstream (1 kb to 50 kb) of RefSeq 
genes. The horizontal line at 1 represents the value expected for random sites. With exception of the integration frequency of SB and HIV into 1 and 2 kb 
around RefSeq genes, the comparison between the experimentally determined integration sites and the random integration sites achieved in all panels 
P ≤ 0.001 (Fisher’s exact test). (c) The fold enrichments of SB, PB, HIV, and MLV insertion sites are plotted over the gene body from the 5′ to the 3′ end. 
Each gene was split into 40 equal bits, and fold enrichment of integration was calculated for each bit. The figure shows fold enrichments of insertion per 
bit averaged over all RefSeq genes. The dashed line marks fold enrichment of 1. (d) Insertions around transcriptional start sites (TSSs). The figure shows 
fold enrichment of insertions around RefSeq TSSs. The numbers of sites at each distance was averaged over all RefSeq genes and smoothed by computing 
the mean in a 500-bp rolling window using the R zoo package. The fold changes were computed after smoothing. The transcription starts at position 0 
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Distribution of vector integration sites with respect 
to genes and TSSs
We next determined the frequencies of integration into 
genomic features including genes, exons, introns, TSSs (TSS ± 1 
kbp), CpG islands and DNaseI hypersensitive sites relative to 
 computer-generated random data sets matched for each of the 
four vector systems (Figure  2 and Supplementary Figure S4). 
Distribution of distance between integration sites outside of genes 
and the nearest gene revealed that intergenic insertions tend to be 
closer to genes than the control datasets (Figure 2a). For example, 
the median distance for HIV integration sites is around 13 kb, 
whereas for the control dataset, it is 85 kb. Out of the four systems, 
the SB transposon insertions are the farthest away from genes 
(median distance 48 kb), suggesting a very low preference for inte-
grating near gene sequences. For PB and MLV, Figure 2a shows a 
bimodal shape reflecting the difference between integration sites 
close to TSS (left peak) and sites more distal to genes (right peak). 
Insertions by all four systems were enriched in genes (Figure 2b) 
(both in exons and introns; Supplementary Figure S4). The pref-
erence of HIV to target genes is well described.20 Remarkably, the 
PB transposon displayed an MLV retrovirus-like insertion profile 
with respect to preferentially targeting the upstream regions of 
genes, whereas the SB transposon displayed the weakest prefer-
ence toward genes (Figure 2b). In the case of MLV, we found a 
significant orientation bias (6% more MLV integrations into genes 
in sense than in antisense direction). Plotting insertion sites over 
the gene bodies revealed high enrichment of both MLV and PB 
insertions at the 5′-ends of genes, whereas HIV insertions tend 
to be enriched in the gene bodies and relatively disfavored at the 
5′- and 3′-ends of genes (Figure 2c). Finally, both PB and MLV 
are enriched (with no significant difference between the frequen-
cies of insertions with sense and antisense orientation) and HIV 
depleted around TSSs (Figure 2d and Supplementary Figure S4).
Interestingly, the MLV insertions concentrate at two peaks 
up- and downstream of the actual TSSs leaving a small drop of 
insertions at the TSSs, whereas PB insertions map directly at 
TSSs (Figure 2d). The bimodal MLV integration pattern can be 
explained by (i) a tendency of retroviruses to direct integration into 
outward-facing major grooves on nucleosome-wrapped DNA51,55 
and (ii) TSSs of expressed genes are nucleosome depleted.56 In 
contrast, high-density integration profiling of the Hermes trans-
poson in Saccharomyces cerevisiae and in Schizosaccharomyces 
pombe revealed a strong association of Hermes integration sites 
with nucleosome-free chromatin.57,58 Target site choice by the 
SB and PB transposons with respect to nucleosomal versus 
 nucleosome-free DNA has not been investigated.
We determined genomic positions of nucleosomes from 
micrococcal nuclease sequencing (MNase-Seq) data,59 fol-
lowed by mapping of our insertion datasets with respect to 
 nucleosome-wrapped versus linker regions. Both SB and PB 
prefer to insert into linker regions (P values <10–14 for SB and P 
value <10–5 for PB, Fisher’s exact test), while MLV slightly prefers 
nucleosomal DNA (P value <0.01, Fisher’s exact test) (Figure 3). 
A similar result was obtained using the Model-based Analysis 
of ChIP-Seq peak calling program60 for determining nucleoso-
mal positions (data not shown). Thus, a possible contribution 
to the characteristic difference between PB and MLV insertion 
patterns at TSSs could be the differential preferences of these ele-
ments to insert into  nucleosome-free versus nucleosomal DNA, 
respectively.
Vector integration positively correlates with gene 
expression levels and gene densities
We next investigated a potential association between the expres-
sional status of genes and the relative frequencies of integrations. 
Transcriptional regulatory elements often coincide with CpG 
islands.61 Indeed, the patterns of integrations at TSSs are mir-
rored for CpG islands in that HIV is depleted, whereas PB and 
MLV are enriched at CpG islands (Supplementary Figure S5). 
SB showed no enrichment at CpG islands. We also investigated 
if the actual methylation status of CpG sites influences integra-
tion. Interestingly, even though both MLV and PB insertions are 
enriched in CpG islands, both elements avoid methylated and 
prefer nonmethylated CpG sites (Supplementary Figure S5). 
Because actively transcribed genes tend to be associated with 
nonmethylated CpG islands, this finding suggests that both MLV 
and PB target transcriptionally active regions, including promot-
ers. Indeed, both MLV and PB integration sites were also found to 
highly correlate to DNaseI hypersensitive sites (Supplementary 
Figure S4).
We next systematically analyzed frequencies of insertions 
and the transcriptional status of genes and their promoters. 
In general, a positive correlation between gene expression and 
integration frequencies can be observed; i.e., integrations tend 
to be depleted in nonexpressed genes but enriched in expressed 
Figure 3 Insertions into nucleosomes versus linkers. We determined 
genomic positions of nucleosomes from MNase-Seq data59 using the 
TemplateFilter program99 with template “Templates_7.1.txt” and default 
parameters. We assumed that the 40-bp regions directly neighboring 
each nucleosome belong to linkers. We then counted all insertion sites 
and control sites falling into the nucleosomes or linker regions. All sites 
outside of these regions were excluded from the subsequent analysis, 
since the chromatin states of these regions were unknown. In order to 
avoid wrong assignments, we only counted sites which were more than 
5 bp away from the nucleosome borders. The figure shows the fractions 
of sites inside of the nucleosomes; the rest of the sites fall into linker 
regions. SB and PB prefer to insert into linker regions (P value < 10−14 
for SB and P value <10−5 for PB, Fisher’s exact test), while MLV prefers 
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Figure 4 Correlation between gene expression and integration into genes and transcriptional start sites. (a) Fold enrichment (i.e., the pro-
portion of experimentally determined integration sites falling into a given set of regions divided by the proportion of control sites falling into the 
same set of regions) of integrations into not expressed (absent = A; 5,603 genes), marginal (M; 5,253 genes), and clearly expressed (present = P; 
6,947 genes) genes. The gene expression levels were determined by59 using Affymetrix Human Genome U133 Plus 2.0 Arrays. The classification 
into A, M, and P genes was done by Schones et al.59 using the Affymetrix GCOS software package. (b) Fold enrichment of integrations for genes of 
different expression level. We split the set of 12,200 marginal or clearly expressed genes into 10 groups (each of 1,220 genes) according to their 
expression level from the lowest (left) to the highest (right) genes. The enrichment is higher for higher expression levels. (c) Fold enrichment (i.e., 
the proportion of experimentally determined integration sites into a window from −1 kb to +1 kb around the TSSs falling into a given set of regions 
divided by the proportion of control sites falling into the same set of regions) of integrations into genes categorized as above. (d) Fold enrichment 
of integrations for genes of different expression levels. HIV was omitted from this plot since the total number of HIV insertions close to TSSs was too 
low. (e) Chromosomal densities of insertions. The relative insertion densities, i.e., the fraction of insertions falling in a certain chromosome divided by 
the fraction of possible insertions falling in this chromosome. In the case of SB, all occurrences of TA dinucleotides are possible insertion sites. In the 
case of PB, all occurrences of TTAA are possible insertion sites. HIV and MLV could integrate at any genomic position. The relative insertion density 
compares the density of insertion to the density of all possible insertion sites. For completely random insertions, the relative insertion density would be 
1; values above 1 mean an enrichment of insertions, values below 1 mean a depletion of insertions. (f) Gene densities, i.e., number of RefSeq genes/
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genes (Figure 4a). Moreover, the enrichment is higher in highly 
expressed than in marginally expressed genes. In other words, 
the stronger a gene is expressed, the more likely it would be 
targeted by any of the four integration systems analyzed here, 
by HIV displaying the most significant correlation (Figure 4a 
and Supplementary Figure  S6). Breaking down gene expres-
sion levels into a larger number of categories indicates that 
the enrichment in insertion frequencies gradually grows with 
increasing expression level (Figure 4b). This is interesting for 
MLV and PB, since they are enriched at TSSs and not in the 
gene bodies. Thus, we also looked at association between the 
expressional status of genes and frequencies of integrations into 
TSSs. Figure 4c shows that HIV is always depleted and PB and 
MLV are always enriched around TSSs, but in all three cases, 
the number of insertions increases with the expression levels. 
However, the level of enrichment for PB and MLV reaches a 
plateau at a certain level of gene expression (Figure 4d). This 
is a hint that for PB and MLV the gene expression level itself 
is less important than the open chromatin state at promoter 
regions. Interestingly, frequencies of SB insertions into TSSs do 
not seem to correlate with the expression levels of the targeted 
genes (Figure 4c,d).
Having seen an overall correlation of integration frequencies 
and genes, we analyzed gene densities across chromosomes and 
found that insertion densities correlate very well with the gene 
densities (Pearson correlation coefficients are between 0.87 and 
0.94; Figure 4e). That is, gene-rich chromosomes including chr17, 
chr19, and chr22 are more frequently hit by insertions, with HIV 
showing the highest enrichment per gene-rich chromosome 
(Figure 4f). The insertion density also correlated with gene cover-
age, i.e., the fraction of bases per chromosome covered by RefSeq 
genes (Pearson correlation coefficients between 0.53 and 0.74, 
data not shown).
Integration sites and chromatin state
We took advantage of the available genome-wide annotation of 
histone mark distributions in human CD4+ T cells62,63 to inves-
tigate potential association with virus/transposon integrations. 
We concentrated on analyzing transposon integration frequencies 
with regard to H3 K4 mono- and trimethylation, a marker for 
active promoter (H3K4me3) and enhancer regions (H3K4me1), 
H3 K27 acetylation (H3K27ac) associated with open chromatin,64 
and trimethylated H3 K27 (H3K27me3) and trimethylated H3 K9 
(H3K9me3), markers for condensed chromatin regions associ-
ated with gene repression.62 The bioinformatic analysis revealed 
an almost random integration profile for SB with only a slight 
bias for euchromatin marks and no bias with respect to hetero-
chromatin marks (Figure 5a). In contrast, the PB transposon as 
well as the MLV and HIV viruses avoid heterochromatin marks 
and are enriched in chromosomal regions characterized by open 
chromatin (Figure 5a). Both PB and MLV are highly enriched in 
chromatin marks associated with TSSs (H3K4me3) and enhancer 
regions (H3K4me1). Differences between PB and MLV become 
visible when inspecting the density of histone marks as a func-
tion of the distance to insertion sites (Figure 5b). In case of marks 
prominent at TSSs, i.e., H3K4me3, Pol II, and CTCF, MLV inte-
gration sites have the characteristic “shifted” peak at a distance of 
about 500–1,000 bp (Figure  5b). A similar distribution of MLV 
insertions was seen with respect to DNaseI cleavage sites, consis-
tent with DNaseI preferentially cleaving nucleosome-free DNA, 
while MLV preferentially inserts into nucleosome-bound DNA. 
Finally, consistent with preferential integration into gene bodies, 
HIV integration sites are highly associated with open chromatin 
characterized by H3K36me3.
Tethering mechanisms affecting SB and PB 
integrations
Chromosomal tethering by interaction of the integration machin-
ery of transposable elements and viruses with host cell-encoded, 
DNA- or chromatin-binding factors may introduce an insertional 
bias in target site selection. Such targeting mechanism, based on 
interactions between LEDGF/p75 and HIV IN, and between BET 
domain proteins and MLV IN is known to play a role in target site 
distribution of HIV21 and MLV,24–26 respectively. Although SB is a 
fish transposon, and the human genome does not contain SB-like 
transposons, DNA sequences resembling the transposase-binding 
sites at the ends of the transposon may occur in human DNA by 
chance, and such sites might be bound by the SB transposase. Can 
Figure 5 Correlation between chromatin state and insertions. (a) Fold enrichment of insertion sites versus control sites in DNaseI hypersensitive 
regions, regions featuring histone modification, and Pol II and CTCF-binding regions. The regions (“tag islands”) were determined by Boyle et al.,63 
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it then be that, in an analogous fashion, the transpositional com-
plex is tethered to chromosomal regions bound by excess trans-
posase molecules during transposition?
We addressed this possibility by mapping our insertion data-
sets with respect to the 5′ GTTTACATACAC 3′sequence motif 
representing the SB transposase core binding site, allowing one 
mismatch in the motif. In total, we found 20,188 occurrences of 
this motif in the human genome. We detected a highly significant 
enrichment of SB insertions within 100 bp of the motifs (Figure 6), 
consistent with a tethering mechanism, in which the transposi-
tional complex is anchored to certain chromosomal sites bound by 
excess transposase molecules (Supplementary Figure S7). Neither 
PB nor the MLV and HIV insertions displayed enrichment close to 
SB transposase-binding sites (Figure 6). Highly significant enrich-
ments of SB insertions could also be found for different window 
sizes and for alternative definitions of SB  transposase-binding 
sites (e.g., all occurrences of 5′ GTTTACATACAC 3′ with up to 
Figure 6 Enrichment of insertions near chromosomal SB transposase-binding sites in the human genome. (a) Fold enrichments of insertion 
sites compared to random controls in up to 100-bp distance of SB transposase-binding sites, i.e., genomic occurrences of 5′ GTTTACATACAC 3′ with 
up to one mismatch. SB integrations are significantly enriched (P value < 1 × 1025, Fisher’s exact test), while the integration frequencies of PB, HIV, 
and MLV compared to their respective backgrounds are not significantly changed. (b) Fold enrichments of insertions sites compared to random 
controls around SB transposase-binding sites, i.e., genomic occurrences of 5′ GTTTACATACAC 3′ with up to three mismatches. The numbers of sites 
at each distance was averaged over all RefSeq genes and smoothed by computing the mean in a 100-bp rolling window using the R zoo package. 
The displayed fold changes were computed after smoothing. There are 3.2 million genomic occurrences of 5′ GTTTACATACAC 3′ with up to three 
mismatches. Four hundred and eighteen out of 8,290 (5%) SB insertions fell directly inside of one of these SB transposase-binding sites, which is a 
highly significant enrichment (P value < 1 × 1015 Fisher’s exact test, fold change 2.02) compared to random controls. The human reference genome 
(hg18) was screened for SB transposase-binding sites using Bowtie.88
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Figure 7 Interaction of the transposase with BET proteins targets piggyBac insertions to BRD4-binding sites. (a) Enrichment of PB and MLV 
insertions near BRD4-associated sites. The fold enrichment of insertions around 33,544 BRD4-binding sites detected by Zhang et al.65 The figure was 
created with the same method as in Figure 2d for TSSs. The numbers of sites at each distance were averaged over all RefSeq genes and smoothed 
by computing the mean in a 500-bp rolling window using the R zoo package. The fold changes were computed after smoothing. The profiles for PB 
and MLV resemble the pattern observed for TSSs. Fifty-three percent of the BRD4-binding sites are inside of RefSeq genes, this explains the relative 
high number of HIV integrations nearby. (b) The PB transposase interacts with the BET proteins BRD2 and BRD4. Extracts of HEK293T cells expressing 
PB-HA along with GFP-tagged BRD2 or BRD4 were immunoprecipitated (IP) with a GFP affinity matrix, and immunoprecipitates were analyzed by 
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2 or 3 mismatches, or all occurrences of 6-mers or 8-mers of 5′ 
GTTTACATACAC 3′; data not shown).
Given the highly similar patterns of PB and MLV insertions 
in our datasets with respect to proximity to TSSs (Figure 2d), we 
wondered if PB insertions are also enriched at sites associated with 
BET proteins. Thus, we next evaluated whether there is a correla-
tion between PB integration sites and the  chromatin-binding sites 
of BET proteins mapped using ChIP-Seq data obtained in CD4+ 
T cells.65 Figure 7a shows a significant  co-localization of BRD4-
binding sites, MLV integration sites, and PB integration sites. The 
data also revealed a very strong enrichment and positioning of 
PB insertion sites directly at the  BRD4-binding sites, whereas 
MLV insertions are positioned at the flanks of the BRD4-binding 
sites. Thus, the correlation between PB and MLV insertions with 
respect to BRD4-binding sites is very similar to the distribution 
of insertions with respect to TSSs as shown in Figure 2d. These 
results suggest that PB, in a fashion analogous to MLV, is possi-
bly targeted to TSSs through a tethering mechanism dictated by 
 chromatin-bound BRD4.
To investigate a possible physical interaction between the PB 
transposase and BET proteins, a co-imunoprecipitation experi-
ment was performed (Figure  7b). Cell extracts were prepared 
from HEK293T cells expressing HA-tagged PB transposase and 
GFP-tagged BET proteins, BRD2 and BRD4. An antibody against 
GFP was used for immunoprecipitation. Precipitated proteins were 
subsequently detected with an antibody against the HA tag of the 
PB transposase. PB transposase was co-precipitated with BRD2 
and BRD4, but not with control (GFP) (Figure 7b, lanes 1, 2, and 
3, respectively). Thus, we conclude that PB transposase interacts 
with BET proteins. We further found that the C-termini of BET 
proteins spanning their highly conserved ET domains that are 
required for interaction with the MLV IN (aa640-801 for BRD2, 
aa539-726 for BRD3, and aa607-722 for BRD4)24–26 was sufficient 
to interact with the PB transposase (Supplementary Figure S8a). 
Finally, we tested if the residues in the BRD2 ET domain that con-
tribute to binding to MLV IN and FeLV IN24 are also involved in 
binding to the PB transposase. We found that none of the residues 
involved in binding to INs are important for interaction with the 
PB transposase (Supplementary Figure S8b). Thus, although PB 
transposase interacts with the ET domain, it does so in a manner 
different from MLV IN and FeLV IN.
Potential deregulation of gene expression upon 
integration and genomic safe harbors
Integration of therapeutic gene constructs into safe sites in the 
human genome would prevent insertional mutagenesis and asso-
ciated risks of oncogenesis in gene therapy. Genomic “safe har-
bors” (GSHs) are regions of the human genome that are able to 
accommodate the predictable expression of newly integrated DNA 
without adverse effects on the host cell or organism. It was previ-
ously proposed that GSHs should meet the following five criteria: 
(i) distance of at least 50 kb from the 5′-end of any gene, (ii) dis-
tance of at least 300 kb from any cancer-related gene, (iii) distance 
of at least 300 kb from any microRNA (miRNA), (iv) location out-
side a transcription unit, and (v) location outside ultraconserved 
regions of the human genome.66,67 We compiled our datasets to 
investigate the relative frequencies of integration into a GSH by 
any of the four integration systems. Figure 8a shows that the viral 
systems have very reduced chance (as low as ~3% for HIV) of 
integrating into a GSH. The PB transposon has a ~12% chance of 
integrating into a GSH, thereby it is expected to be safer than the 
two viruses. However, based on these criteria, the SB transposon is 
predicted to be the safest in a therapeutic context, with an overall 
chance of ~20% of integration into GSHs.
Some of the adverse events observed in HSC-based clinical 
trials revealed a clonal imbalance in reconstituted hematopoi-
esis in patients associated with gammaretroviral insertions into 
the LMO2 (refs. 9–12,14), MN1 (14), CCND2 (9), BMI1 (ref. 9), 
MECOM/MDS1/EVI1 (refs. 13,14), PRDM16 (68), and SETBP1 
(68) genes, and some of these insertions have been shown to be 
causally linked to oncogenesis. Because our insertional datasets 
allow us to assess relative enrichment of integrations in genes 
in the absence of biological selection, we wondered if any of the 
genes recovered in the clinical trials are actually favored targets by 
the four vector systems. Figure 8b reveals that MLV indeed favors 
integration into some of these genes with SETBP1 favored more 
than twofold over random chance to be hit. Thus, vector choice 
greatly influences the relative chance of insertional oncogenesis in 
gene therapy clinical trials.
Although lentiviral vectors have long been considered to be 
safe for genetic engineering in differentiated T cells, HIV inte-
grations have been recently associated with clonal cell expansion 
in AIDS patients.17,18 Some of these HIV integrations occurred 
in genes playing roles in cell growth, development, and cancer, 
suggesting that proviral integrations into some of these genes can 
drive biological selection on the level of cell survival and selective 
proliferation. We selected a total of 29 genes from these two stud-
ies (these genes were recovered in two out of three patients in the 
Wagner et al. study or in two out of five patients in the Maldarelli 
et al. study) and analyzed if any of them is a favored target by the 
four vector systems. Figure 8b reveals that 55% (16/29) of these 
genes are favored by MLV, 41% (12/29) by HIV, and 24% (7/29) by 
PB, with significant overlap between these gene lists. For example, 
five genes (CYTH1, IKZF3, NFATC3, RPTOR, and TNRC6B) are 
mutually favored by MLV, HIV, and PB. Not a single gene from 
this list appears to be preferentially targeted by SB. Thus, the data 
reveal that vector choice can greatly contribute to a reduced like-
lihood of insertional mutagenesis of genes implicated in driving 
clonal dominance in T cells.
DISCUSSION
DNA-based, cut-and-paste transposons display a wide spectrum 
of selectivity with respect to chromosomal integration. In this 
work, we mapped ~9,000 de novo SB and PB insertions in primary 
human CD4+ T cells and compared their insertion profiles with 
those of the MLV retrovirus and the HIV lentivirus. Our bioin-
formatic analyses included mapping against the T cell genome 
with respect to proximity to genes, TSSs, CpG islands, DNaseI 
hypersensitive sites, chromatin marks, and transcriptional status 
of genes (Supplementary Table S1). The SB transposon displayed 
the least deviation from random with respect to genome-wide dis-
tribution: no apparent bias was seen for either heterochromatin 
marks or euchromatin marks, and only a weak correlation with 
transcriptional status of targeted genes was detected (Figures 2, 
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Figure 8 Insertions into genomic safe harbors and selected genes. (a) Instead of “ultra-conserved” regions, we used a database of regions con-
served in primates created by the phyloP program from the PHAST package (phyloP46waysPrimates downloaded from UCSC table browser). A list 
of 3,165 cancer-related genes was downloaded from http://cbio.mskcc.org/CancerGenes. “Safe harbor” is defined as the intersection of the five 
conditions: not conserved, >300 kb from cancer genes and miRNA genes, >50 bp from TSS, and outside of genes. The error bar for “control” results 
from the divergences of the four different control sets. (b) Relative enrichment of Sleeping Beauty and piggyBac transposon, MLV retrovirus, and HIV 
lentivirus integration sites in selected genes. Number of integration sites into genes and their relative enrichment compared to control sites is shown. 
The list contains selected genes that were either insertionally deregulated by MLV-based vectors in gene therapy clinical trials leading to oncogen-
esis or that were found to be associated with HIV insertions and a clonal imbalance in the T cell repertoires of AIDS patients. The table contains the 
number of insertion sites in the given genes and the relative enrichment of integration sites compared to the respective set of random control sites. If 
no integration site was recovered in a given gene, then this enrichment is set to “0x.” P values were calculated using Fisher’s exact test; multiple test 
correction was done using the Benjamini–Hochberg method. Significant enrichments (corrected P values ≤ 0.05) are marked orange.
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4, and 5). This is in marked contrast to target site distributions of 
several other transposons including Tol2 (refs. 39,41), TcBuster,43 
SPIN,43 and PB39,41,43,48 that all show significant difference from 
random insertion with respect to favored integration into genes 
and near chromatin marks characteristic of active transcription 
units (e.g., H3K27 acetylation and H3K4 monomethylation) and 
disfavored integration near marks characteristic of inactive chro-
matin (e.g., H3K27 trimethylation). The PB transposon, in par-
ticular, has been shown to favor open chromatin, expressed genes, 
and TSSs (±5 kb) associated with DNaseI hypersensitive sites, 
H3K4me3 marks, and Pol II-bound regions in mouse and human 
cells.44,46–48,50,53
We have identified remarkable parallels between integration 
site distributions of the PB transposon and the MLV retrovirus 
across 40 different chromatin states defined by combinations of 
genomic features specified in 70 datasets (Figure 1). Both PB and 
MLV were highly enriched in chromatin marks associated with 
TSSs (H3K4me3), in regions characterized by Pol II and CTCF 
binding, in proximity to expressed genes and in genes with higher 
expression levels (Figures  2, 4, and 5), suggesting that a major 
determining factor of insertion site distribution is physical acces-
sibility of chromatin. Our studies, however, also highlight the 
potential involvement of an active mechanism of shaping the 
characteristic, MLV-like insertion profile of the PB transposon. 
Namely, PB insertions co-localize with BRD4-associated sites at 
TSSs, and the PB transposase interacts with BET proteins, includ-
ing BRD4 (Figure 7). Recent studies revealed the role of an inter-
action of the MLV IN with BET domain proteins in tethering the 
viral pre-integration complex to TSSs,24–26 and our results sug-
gest a similar mechanism influencing PB integration. Although 
both the PB transposase and the MLV IN are DDE recombinases, 
these two proteins are only distantly related; therefore, a BRD/
BET  protein-dependent tethering mechanism in their chromo-
somal integration process is likely a result of convergent evolution. 
Indeed, in addition to MLV, some other viruses exploit cellular 
BET proteins for different aspects of their life cycle (reviewed in 
ref. 69). One prominent mechanism is anchoring of the episomal 
genomes of papillomaviruses,70,71 Kaposi’s sarcoma-associated her-
pesvirus,72–75 and Epstein–Barr virus76 to either interphase chro-
matin or mitotic chromosomes by interactions of viral proteins 
with BET domain proteins. Thus, tethering mechanisms relying 
on interactions between virally encoded factors and BET proteins 
appear to have independently arisen during viral evolution.
Despite the similarities, a close inspection of the integration 
sites of PB and MLV at TSSs revealed a characteristic difference: 
the MLV insertions map at two peaks just up- and downstream of 
the TSSs, whereas PB insertions map directly at TSSs (Figure 2d). 
The bimodal MLV integration pattern is likely the result of 
a preference of MLV to integrate into nucleosome-wrapped 
DNA51,55 and that TSSs of expressed genes tend to be nucleosome 
depleted.56 We have shown that, in contrast to MLV, PB insertions 
favor nucleosome-free DNA (Figure 3), thereby providing a likely 
explanation for the characteristic difference between PB and MLV 
insertion patterns at TSSs.
We provide evidence for enriched insertion of the SB transpo-
son near chromosomal sites that resemble binding sites of the SB 
transposase (Figure 6). These data are consistent with a tethering 
mechanism that involves interaction of the transpositional nucleo-
protein complex with chromatin-bound excess transposase mol-
ecules (Supplementary Figure S7). It has been proposed that 
SB transposition involves a transposase tetramer associated with 
the transposon ends.77 Can it be that this tetrameric complex can 
establish contacts with additional transposase molecules bound 
elsewhere in the genome? Although the relative contributions of 
the four transposase monomers to the catalytic steps of transpo-
sition have not been elucidated, it is possible that not all mono-
mers are equally engaged in the reaction. Indeed, the bacterial Mu 
transposase forms a stable tetramer with the Mu DNA ends but 
only two of the active sites within the tetramer are involved in 
catalysis.78–80 Although the other two subunits of the tetramer do 
not supply DDE residues to the active sites, they are likely to play 
other important roles, including maintaining the structural integ-
rity of the transpososome.81,82 Similarly, the foamy virus retrovi-
ral intasome structure revealed a tetramer of IN, but the catalytic 
DDE residues are contributed by only two IN subunits.83 Thus, 
other mobile elements (including SB) may also require “surplus” 
recombinase subunits for temporarily stabilizing pairing of the 
transposon ends and for the formation of a catalytically primed 
synaptic complex.
Finally, our data allow us to estimate the relative safety of the 
four integrating genetic elements in the context of human appli-
cations (Figure 8). Our compiled datasets allow us to rank these 
vector systems with respect to their projected relative “safety” 
based on the frequencies of integration into GSHs (Figure 8a) as 
well as into selected genes that were targeted by retroviral inser-
tions in gene therapy clinical trials leading to serious adverse 
events or by HIV insertions on AIDS patients leading to a clonal 
imbalance in their T cell repertoire (Figure 8b). Our analyses col-
lectively establish a favorable integration profile of the SB transpo-
son. It has to be noted that those insertions that are not in GSHs 
are not necessarily equally genotoxic. Indeed, it has been dem-
onstrated that MLV-based gammaretroviral insertions, although 
they target GSHs >2-fold more frequently than HIV-based len-
tiviral vectors (Figure  8a), were approximately threefold more 
likely to trigger transformation of primary HSCs in a cell-based 
immortalization assay.84 This suggests that an MLV insertion next 
to a TSSs tends to be more genotoxic than an HIV insertion in a 
gene body. Furthermore, the mutagenic potential of any integrat-
ing gene vector will ultimately be defined not only by its inser-
tional pattern, but also by its cargo (including the transcriptional 
regulatory elements that drive transgene expression) and by vec-
tor copy number per genome. Importantly, vector copy number 
can be experimentally adjusted by titrating the components of the 
SB transposon system in the electroporation reactions to yield pri-
marily one or two insertions per cell,39 very much like multiplicity 
of infection largely determines vector copy number in viral vec-
tor transductions. Finally, important steps have been made toward 
introducing an experimental bias into the natural target site selec-
tion properties of integrating gene vector systems. First, for both 
the SB42 and the PB85 transposon systems, it has been shown that 
engineered DNA-binding domains can drive at least a fraction of 
integration events into a chromosomal locus or region defined by 
sequence-specific DNA–protein interactions, suggesting a pos-
sibility to target vector integrations into validated GSHs in the 
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future. Second, disrupting the interaction of BET proteins with 
the MLV preintegration complex by targeted mutagenesis of IN 
has been shown to result in detargeting of TSSs, thereby yielding 
a potentially safer genome-wide insertion profile.86 Thus, continu-
ing efforts of vector engineering will likely have a considerable 
impact on the safety of future vector designs.
MATERIALS AND METHODS
Vector construction. Transposase expression vectors pCaggs-SB100 and 
pCaggs-pB were kindly provided by Grabundzija.39 The transposon vectors 
pUC19SBCaggsGFP and pUC19pBCaggsGFP were generated by replac-
ing the SV40neo cassette in pUC19SBneo and pUC19pBneo39 by a Caggs 
promoter-driven GFP expression cassette.
Isolation of human peripheral blood mononuclear cells and enrich-
ment of CD4+ T cells. After obtaining informed consent, venous blood 
from healthy volunteers was drawn into ethylenediaminetetraacetic 
 acid-containing tubes (S-Monovette, Sarstedt, Nümbrecht, Germany) 
and diluted 1:2 with buffer (phosphate-buffered saline (PBS), 2% 
 heat-inactivated fetal calf serum). The diluted blood was layered onto 
Biocoll separating solution (Biochrom AG, Berlin, Germany) at a volume 
ratio of 2:1, and after centrifugation for 20 minutes at 648 x g without 
brake and low acceleration, the layer of mononuclear cells was aspirated. 
Peripheral blood mononuclear cells were washed twice with buffer (first 
cycle, 10 minutes at 300 xg; second cycle, 10 minutes at 200 xg), and the cell 
density was adjusted to 5 × 107/ml.
CD4+ T cells were isolated from peripheral blood mononuclear 
cells by negative immunomagnetic selection using the EasySep Human 
CD4+ T Cell Enrichment Kit (Stemcell Technologies, Grenoble, France) 
according to the manufacturer’s instructions. Hundred microliter 
antibody cocktail were added to 1 × 108 peripheral blood mononuclear 
cells in 2 ml buffer and incubated for 10 minutes at room temperature. 
Hundred microliter magnetic particles were added, and after 5 minutes 
of incubation at room temperature, the cell suspension was adjusted to 
2.5 ml by adding buffer. The tube was placed into the EasySep magnet 
(Stemcell Technologies, Grenoble, France), and after 5 minutes, the 
unlabeled CD4+ T-cell fraction was poured off into a new tube.
Electroporation, activation, and expansion of T cells. T cells were 
electroporated using the Nucleofector I device and the Human T cell 
Nucleofector Kit (Lonza, Cologne, Germany) following the instructions 
of the manual except for cell number and DNA amount. 6 × 106 cells were 
mixed with 10 µg plasmid DNA (transposon to transposase ratio of 1:2) in 
100 µl  DNA-nucleofector solution and electroporated using the program 
U-14. RPMI 1640 Glutamax (Life Techologies, Darmstadt, Germany) 
 supplemented with 10% heat-inactivated fetal calf serum (Biochrom, 
Berlin, Germany) and 10 mmol/l HEPES was used as T cell medium 
(TCM). Immediately after the electroporation, 0.5 ml TCM was added to 
the cuvette, the cell suspension was transferred into a 24-well tissue cul-
ture plate containing 1.5 ml pre-warmed TCM, and cultured overnight in a 
humidified incubator at 37 °C and 5% CO2.
T cells were activated 24 hours after electroporation by transfer into 
a new plate precoated with 5 µg/ml anti-CD3 and 1 µg/ml anti-CD28 
antibodies (BD Pharmingen, Heidelberg, Germany) and addition of 100 
UI/ml IL-2 (Proleukin, Novatis, Basel, Switzerland). After 3–4 days, the 
activated T cells were transferred into a new cell culture flask, and 2–3 ml 
TCM supplemented with 100 UI/ml IL-2 was added daily.
Analysis of T cells by flow cytometry. The transposon vectors were tagged 
with a GFP expression cassette that allowed an estimation of the respective 
transfection and transpositional efficiencies at day 1 and day 10 post elec-
troporation. Sustained GFP expression, as judged by  fluorescence-activated 
cell sorting (FACS) analysis, in the presence of the respective transposases 
is indicative of stable, transposon-mediated genetic modification of 
human CD4+ T cells (Supplementary Figure S1a). Both transposon sys-
tems were about equally efficient in stable gene transfer and resulted in 
~40% GFP+ cells. For FACS analysis, cells were washed and incubated with 
APC-labeled anti-human CD4 antibody (BD Pharmingen, Heidelberg, 
Germany) in FACS buffer (PBS, 2% fetal calf serum, 2 mmol/l ethylene-
diaminetetraacetic acid, 0.05% NaN3) for 30 minutes at 4 °C and washed 
twice afterwards. Before measurement, SYTOX blue (Life Technologies, 
Darmstadt, Germany) was added to stain dead cells. Flow cytometry data 
was acquired using a FACS canto II (BD Bioscience, Heidelberg, Germany), 
and data were analyzed with FlowJo software (TreeStar, Ashland, OR).
Recovery of integration sites. Unsorted cell populations at day 10 
 post-electroporation were harvested for genomic DNA preparation. Two 
variations of the linear amplification-mediated PCR87 were performed to 
amplify the vector–genomic DNA junctions. For both approaches, T cells 
were harvested 10 days after electroporation, and genomic DNA was 
extracted using the DNeasy kit (Qiagen, Hilden, Germany). Five micro-
gram of genomic DNA was either predigested with DpnI and BamHI 
(SB) or DpnI and KpnI (PB) or sonicated to small pieces ranging from 
100 to 500 bp, with an average size of 250 bp using the Covartis S2 sonica-
tion device. Thereafter, the sonicated DNA was ethanol precipitated. The 
digested DNA was subjected to gel electrophoresis, and the genomic DNA 
was isolated from 0.7% agarose gel and purified using GenElute Gel extrac-
tion kit (Sigma-Aldrich, St Louis, MO). For both, 500 ng DNA was used for 
linear amplification-mediated PCR. Biotinylated SB- and PB- transposon 
inverted terminal repeat-specific primers (see Supplementary Materials 
for primer sequences) were used in 50 rounds of linear amplification to 
enrich DNA species containing transposon–chromosomal DNA junctions. 
The single-stranded products were immobilized on streptadivin-coated 
magnetic beads using the Dynabeads kilobase BINDER kit (Invitrogen, 
Carlsbad, CA). All subsequent steps were performed on the magnetic 
bead-bound DNA. Repeated washing steps with water followed each 
reaction. Second strand synthesis was performed with random hexamer 
oligos (Roche, Basel, Switzerland) using Klenow (New England Biolabs, 
Ipswich, MA). The free ends of the double-stranded sonicated DNA were 
blunt ended and phosphorylated using the End-ItDNA End-Repair kit 
(Epicentre, Madison, WI). Klenow fragment exo- (New England Biolabs) 
and dATP were used to add a single “A” nucleotide to the 3′ ends. The 
double-stranded DNA of the second approach was subjected to restric-
tion digests with MboI, HpaII, or CviQI. The DNA fragments with an “A” 
overhang were ligated to linkers with a “T” overhang, whereas the digested 
DNA was ligated with linkers having the equivalent overhang created by 
the respective restriction enzyme. Next, the bead-bound DNA was sub-
jected to a PCR using primers specific for the inverted terminal repeat 
sequences and the linkers. During the amplification, we used barcoded 
primers so that we could pool different libraries. Finally, primers corre-
sponding to Illumina adapter sequences were used to yield a directional 
library, in which sequences complementary to the Illumina genomic DNA 
sequence primers were located upstream to the transposon inverted ter-
minal repeats. Thus, the resulting libraries could be pooled and sequenced 
on a single flow cell lane on the Illumina HiSeq platform with single end 
run settings.40
Analysis of sequencing data. We selected all sequencing reads which 
passed the quality filter of the Illumina real-time analysis program and 
which started with the barcode (exact sequence) and the transposon 
inverted terminal repeat-specific primer sequences (with up to one mis-
matches). The rest of the reads (27 bp for SB starting with TA dinucleotide, 
and 30 bp for PB starting with TTAA) were mapped to the human genome 
(hg18, downloaded from genome.ucsc.edu) using the following procedure 
to avoid spurious insertion sites. First, we determined all sequencing reads 
mapping exactly to one or more positions within the reference genome 
using Bowtie.88 The resulting reads were mapped against each other and 
then clustered such that any two reads with up to two mismatches belong 
to the same cluster. We kept only reads which occurred at least twice and 
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contributed at least one-fifths of the total number of reads within their 
cluster. From the resulting reads, we kept only those which mapped exactly 
to a unique position in the reference genome. Reads mapping to the same 
TA (in the case of SB) or TTAA (in the case of PB) sequence in the genome 
were then merged together. Sequence data is accessible in the GEO data-
base at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wtsfakacnv
yfroz&acc=GSE58744.
Generation of control sites. We created sets of control sites for SB and 
PB separately; 12 control sites per insertion site. The four protocol vari-
ants, i.e., using sonication or digestion with MboI, HpaII, or CviQI, require 
slightly different methods of control site selection. For insertion sites found 
by sonication, we randomly selected the control sites from all occurrences 
of TA (in the case of SB) or TTAA (in the case of PB) in the genome. For 
insertion sites found by enzyme digestion, we selected occurrences of TA/
TTAA having the same distance to the closest enzyme restriction site as 
the original insertion site. Since each insertion site could be found by any 
of these four protocol variants, we adjusted the number of control sites 
accordingly: if, for example, one insertion site was found both by soni-
cation and Mbol, then we created six control sites using the sonication 
method and six control sites using the Mbol method. We then retrieved 
the genomic sequences at the control sites, 27 bp in the case of SB and 30 bp 
in the case of PB, and then processed them in the same way as the sequenc-
ing reads (see above) keeping at the end only the uniquely mapped control 
sites. For HIV and MLV, we used the random control sites described by 
Roth et al.51
ChromHMM analysis. The following ChIP-Seq data sets were retrieved from 
various public repositories: BRG1 (ref. 89), CTCF, H2BK5me1, H3K27me1, 
H3K27me2, H3K27me3, H3K36me1, H3K36me3, H3K4me1, H3K4me2, 
H3K4me3, H3K79me1, H3K79me2, H3K79me3, H3K9me1, H3K9me2, 
H3K9me3, H3R2me1, H3R2me2, H4K20me1, H4K20me3, H4R3me2 
(ref. 62), PolIII,90 HMGN1, YY1 (ref. 91), STAT1, STAT4, STAT5A, 
STAT5B,92 gH2AX, H2AX, H2AZ, INO80, SRCAP,93 H2AK5ac, H2AK9ac, 
H2BK120ac, H2BK12ac, H2BK20ac, H2BK5ac, H3K14ac, H3K18ac, 
H3K23ac, H3K27ac, H3K36ac, H3K4ac, H3K9ac, H4K12ac, H4K16ac, 
H4K5ac, H4K8ac, H4K91ac,94 CBP, MOF, p300, PCAF, Tip60, HDAC1, 
HDAC2, HDAC3, HDAC6 (ref. 95), BRD4, PolII, PolIIS2P, and PolIIS5P.65 
Moreover, we used DNase-Seq data,63 total RNA-Seq90 and polyA RNA-Seq 
data,65 and MRE and MeDIP assays measuring DNA methylation.96
For creating sets of genomic features, we downloaded genome 
annotation files from the UCSC Genome Bioinformatics Site (http://
genome.ucsc.edu). The splitting of genes into the groups “absent,” 
“marginal,” and “present” according to their expression levels was done as 
described in ref. 59. DNase hypersensitive sites were taken from  ref. 63. 
The set of enhancer regions (called “permissive enhancers”) was taken 
from FANTOM 5 data base.97 Lamina-associated domains were taken 
from ref. 98. Conserved regions and safe harbors were defined as 
described in refs. 66,67.
Co-imunoprecipitations. HEK293T cells were co-transfected, using 
Fugene 6 (Roche, Mannheim, Germany), with 1 µg of DNA of expres-
sion vectors for HA-tagged PB transposase and GFP-tagged BRD2, BRD4, 
the C-terminal domains of BRD2 (aa640-801), BRD3 (aa539-726), BRD4 
(aa607-722), or BRD2 mutants, as described previously.24 Forty-eight hours 
after transfection, cells were lysed once in cold PBS and lysed in 300 µl of 
RIPA buffer (25 mmol/l Tris, pH 7.4, 150 mmol/l NaCl, 10 mmol/l MgCl2, 
10 mmol/l DTT, 0.5% NP-40). A polyclonal antibody to GFP (Clontech, 
Saint-Germain-en-Laye, France) was immobilized on Protein A sepharose 
beads (GE Healthcare, Freiburg, Germany) by washing 100 µl of beads 
three times with 500 µl of RIPA buffer, adding 200 µg of anti-GFP antibody 
diluted in 45 µl PBS containing 4% sucrose and 0.02% Na-azide, incu-
bating the beads for 15 minutes, adjusting the volume to 300 µl PBS/4% 
sucrose/0.02% Na-azide and allowing the antibody to bind to the beads 
overnight at 4 °C on a roller-shaker. Following three washes in RIPA buf-
fer, beads were resuspended in 250 µl of RIPA buffer, 250 µl of cell extract 
was mixed with 20 µl of anti-GFP beads and incubated overnight at 4 °C. 
Afterwards, beads were washed eight times with 500 µl RIPA buffer with 
protease inhibitors, bound proteins eluted with sodium dodecyl sulfate-
polyacrylamide gel electrophoresis sample buffer, and analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis  and western blot.
SUPPLEMENTARY MATERIAL
Figure S1. Sustained GFP expression in human CD4+ T cells after 
genetic modification using the Sleeping Beauty and piggyBac transpo-
son systems.
Figure S2. Local sequence information content at vector integration 
sites.
Figure S3. Genome-wide mapping of Sleeping Beauty and piggyBac 
integrations in primary human T cells.
Figure S4. Insertions into genomic features.
Figure S5. Integration and DNA-methylation.
Figure S6. Correlation between gene expression and integration 
into genes.
Figure S7. A model for a tethering mechanism in Sleeping Beauty 
transposon integration that involves interaction between the trans-
positional nucleoprotein complex and chomatin-bound excess trans-
posase molecules.
Figure S8. The PB transposase interacts with the BET proteins BRD2 
and BRD4 via their C-termini.
Table S1. Summary of genomic features around insertion sites.
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